0 CHECKOUT

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015

  • ID: 3446759
  • September 2015
  • 77 pages
  • Global Markets Direct
1 of 3

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015

Summary

The report ‘Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H2 2015’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chemotherapy Induced Peripheral Neuropathy, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Peripheral Neuropathy and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party READ MORE >

Note: Product cover images may vary from those shown
2 of 3

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Chemotherapy Induced Peripheral Neuropathy Overview

Therapeutics Development

Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview

Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis

Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies

Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes

Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies

Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development

DARA BioSciences, Inc.

DermaXon, LLC

Eisai Co., Ltd.

Immune Pharmaceuticals Inc.

Laboratorios Del Dr. Esteve S.A.

MAKScientific, LLC

Mertiva AB

Panacea Pharmaceuticals, Inc.

PharmatrophiX, Inc.

Spectrum Pharmaceuticals, Inc.

Spinifex Pharmaceuticals Pty Limited

Virobay Inc.

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(amitriptyline + ketamine hydrochloride) - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AL-309 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AM-1710 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Drug for Pain - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DX-0332 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-2072 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

E-52862 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

EMA-401 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

KRN-5500 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LM11A-31 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PAN-811 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PGN-703 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SPI-205 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

VBY-036 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones

Featured News & Press Releases

Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA

Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program

Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA

Mar 28, 2012: Allon Receives US Patent Covering Use Of Its Neuroprotective Technology Platform

Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation

Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2015

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Investigation by Universities/Institutes, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by DARA BioSciences, Inc., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spinifex Pharmaceuticals Pty Limited, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Assessment by Combination Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H2 2015

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2015

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.